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ABSTRACT
Dengue fever virus (DENV) is said to be a single-stranded, positive-sense RNA virus that belongs to the family Flaviviridae and the genus is Flavivirus. 
The disease can be transmitted through infected blood products and also through organ donation. Vertical transmission (from mother to child) at 
the time of pregnancy or during birth has been reported. Other unusual reports showed man-to-man modes of transmission. Hemorrhagic fever is 
specified by hemorrhage, thrombocytopenia, leakage of blood plasma, or dengue shock syndrome. Dengue is basically transmitted by various species 
of mosquito among the genus Aedes, the most uniquely identified one is Aedes aegypti. There are four different but very closely related serotypes 
(DENV-1, DENV-2, DENV-3, and DENV-4) of the virus that causes Dengue. Lifelong immunity against the particular serotype that has caused the 
infection is believed to have been imparted upon recovery. However, cross-immunity to the other serotypes is either partial or temporary upon 
recovery and hence future infections by any of the other serotypes enhance the risk of developing severe dengue. Prevention is identified by reducing 
the habitat and the number of mosquitoes and also by limiting exposure to bites. Treatment of mild or moderate type is supportive, with oral or 
intravenous rehydration. The intravenous fluids and blood transfusion for more severe cases are found to be effective. The present study aimed 
to present brief and informative salient features of various facts regarding dengue, including its global incidence, structure, mode of transmission, 
clinical signs and symptoms, control, and preventive measures.
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INTRODUCTION
Dengue, also known as break-bone fever, is an arthropod-borne viral 
disease and recently has become a global health concern [1]. This 
disease prevailed primarily in the equatorial regions of Africa, the 
Americas, South East Asia, and the Western Pacific. The incidences of 
dengue fever (DF) have increased dramatically since the 1960s [2]. The 
word “dengue” is derived from the Swahili (a Bantu language spoken 
in much of East Africa by about 140 million people) phrase “ka-dinga 
pepo” that describes the disease caused by an evil spirit. The Swahili 
word Dinga originated from the Spanish word “dengue,” meaning 
fastidious or careful, describing the gait of a person suffering the bone 
pain of DF. The term Break Bone Fever was applied by Benjamin Rush 
in 1789, as reported from the Philadelphia epidemic. He used the name 
“bilious remitting fever.” The term DF came into use after 1828 [3].
The pattern of incidences of dengue in the Southeast Asia Region is 
periodic and the situation of an epidemic in various countries varies 
differently not only from time to time but also from place to place [4]. 
Indonesia has been estimated as the country with the highest economic 
burden of dengue in the region [5]. Dengue in Indonesia was first 
reported in 1968 in Jakarta (DKI Jakarta) and Surabaya (East Java). 
Incidence of dengue over the past 45 years increased at a tremendous 
rate, shifting from young children to older age groups [6]. At present, 
geographical transmission pattern of dengue has changed from almost 
entirely an urban disease too much more a rural one [7]. However, 
most of the reported dengue cases are from areas with maximum 
population density, such as provinces in Java, Bali, and Sumatra [8]. 
Dengue infection has a vast clinical illness spectrum, starting from 
asymptomatic or undifferentiated febrile illness (viral syndrome), 
DF, dengue hemorrhagic fever (DHF), and to dengue shock syndrome 
(DSS) [9]. Dengue infection causes complications in the nervous system 
and other clinical complications, accompanied by sequelae or fatal 
consequences. An existing early warning for dengue in Yogyakarta 
has been able to categorize an epidemic year depending on disease 
surveillance and sea surface temperature anomalies data [10]. 
However, this has the limitation at the same time as it only tries to 
estimate the nature of the next year’s epidemic activities. Meanwhile, 
another study conducted in Yogyakarta shows that there is more 
than one peak of the monthly number of dengue cases that took place 
throughout the year [11]. In addition, a study conducted in Singapore 
provides evidence that dengue can be forecasted with good precision 
up to 16 weeks ahead by the use of appropriate disease surveillance 
data and information on the meteorological conditions before the 
onset of the upsurge [12]. Therefore, it may be possible to develop 
an early warning that is capable of estimating the nature of the next 
1 or 2-month’s epidemic activities for Yogyakarta. With an incubation 
period of 3–10 days, the illness initiates with acute onset of high fever, 
typically accompanied by other symptoms such as headache, myalgia, 
arthralgia, and sometimes a characteristic maculopapular skin rash 
mostly similar to measles. Most of the infected people develop any of 
the symptoms as mentioned and most of those who do have symptoms 
recover spontaneously. However, in a small proportion of cases, the 
disease progresses to a more severe life-threatening form.
The non-rural acquainted chief vector Aedes aegypti mosquito is 
distributed across tropical and subtropical latitudes. Moreover, 
the geographic range of a secondary vector, Aedes albopictus, has 
dramatically dilated in recent years [13]. Maturation of trade, particularly 
the trade of tires arising out of used vehicles, musing the explanation 
of the dispersal of eggs and immature forms of these arboviral vectors 
into different territories [14]. Vector control by chemical or biologic 
targeting of mosquitoes and abolition of their breeding sites is the 
centerpiece of dengue prevention, but to stop disease transmission in 
roughly all countries where dengue is endemic, this perspective is not 
effective. The lack of deep-rooted cross-immunity among the four virus 
types allows multiple sequential infections, so the antigenic diversity of 
the dengue virus (DENV) is supreme. Therefore, the spread of dengue 
encapsulates how global trade (transport of the mosquito vectors), 
increasing travel inward and between countries (the movement of 
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viremic people), urban crowding (conducting multiple infections 
from an infected mosquito), and worthless vector-control strategies 
prevailed a pandemic in the modern era. With the flooding worldwide 
spread of dengue, rehearsing doctors in mild North America, Europe, 
Australia, and Japan are all inbound to see returning voyagers with 
dengue disease. The diagnosis should be contemplated in any patient 
exposed to fever developed within 14 days after even a momentary trip 
to the tropics or subtropics, including those regions where dengue has 
not traditionally been considered an endemic disease [15].
GLOBAL INCIDENCE OF DENGUE
The sequence of the disease associated with dengue from 1780 to 1940 
was specified by relatively rare, often large epidemics. The DENV, an 
emerging health issue, estimated 390 million infections prevailing 
annually across the globe [16]. The first recorded case of probable DF 
was in a Chinese medical encyclopedia from Jin Dynasty (265-420AD), 
referred to as “water poison” typically associated with flying insects. 
In 1906, it was confirmed that Aedes mosquitoes transmit the DF. In 
1907, Dengue became the second disease after “yellow fever,” caused by 
virus. DHF was first reported in the Philippines in the year 1953 and in 
South America in 1981 [17]. DF is endemic in more than 100 countries, 
with maximum cases reported from the Americas, South-East Asia, and 
Western Pacific regions according to the WHO. In Asia, epidemic DHF 
expanded geographically from Southeast Asian countries west to India, 
Sri Lanka, the Maldives, and Pakistan, and East to China [18]. Different 
islands of the South and Central Pacific region (Niue, Palau, Yap, Cook 
Islands, Tahiti, New Caledonia, and Vanuatu) went through more or less 
major DHF epidemics [19]. Epidemiologic differences in the Americas, 
however, have been the most reasonable. In 1950s, 1960s, and mostly 
1970s, epidemic dengue was thin on the ground in the American region 
owing to the fact that the predominant mosquito vector, A. aegypti 
suppressed from most of Central and South America [20]. In India, 
dengue is endemic in almost all states and is one of the leading causes 
of hospitalization. Spying for DF in India is performed through a 
network of more than 600 sentinel hospitals under the National Vector 
Borne Disease Control Program [21], Integrated Disease Surveillance 
Program [22], and a network of 52 Virus Research and Diagnostic 
Laboratories that is established by Department of Health Research [23]. 
However, by 1980s, the American region started experiencing drastic 
epidemics of dengue in countries that had been at liberty of the disease 
for about 35–130 years [24]. New DENV strains and serotypes were set 
in motion (In 1977 DEN-1, in 1981a new strain of DEN-2, DEN-4, and in 
1994 a new strain of DEN-3). From 1981 to 1997, a total of 24 American 
countries reported confirmed DHF through laboratory tests [25]. Africa 
has not yet had a paramount epidemic of DHF still; occasional cases 
have occurred, with escalated epidemic dengue fever, in the past 15 
years. Before the 1980s, limited was known about the distribution 
of DENVs in Africa. Since then, major epidemics caused by all four 
serotypes have prevailed in both East and West Africa. Waves have been 
more common in East Africa and the Middle East in the 1990s, with 
the highest epidemics in Djibouti in 1991 and in Jeddah, Saudi Arabia, 
during 1994; both were the first flare-up in those countries in over 50 
years [26]. Over 2.5 billion people now survive in areas where dengue 
is endemic (Fig. 1) [27].
VIROLOGIC ATTRIBUTES
Female Aedes (Ae.) mosquitoes of the subgenus Stegomyia transmit 
the DENV to the human. The most important epidemic vector in the 
tropical and subtropical regions being A. aegypti. Other species such as 
A. albopictus, Aedes polynesiensis, member of Aedes scutellaris complex, 
and Aedes niveus have been found to enact as secondary vectors [28]. 
However, A. niveus is considered only as a sylvatic (Fraction of the 
pathogen population’s lifespan spent cycling between wild animals and 
vectors. Humans are usually an incidental or dead-end host, infected 
by them) vector. Depending upon the extent of feeding, the life cycle 
of Aedes mosquito lasts for about 8–10 days, specifically at room 
temperature. It is having two phases namely aquatic (larvae, pupae) and 
terrestrial (eggs, adults) phase. At present, A. albopictus has become an 
effectively important vector because it is capable of easy adaptability in 
new environments together with temperate regions. A. aegypti spread 
to different countries has created opportunities for DENVs to enter 
new locations and cause disease [29]. Nevertheless, it is still a minor 
contributor to human dengue infections.
Dengue mainly caused by one of the four single-stranded and positive-
sense RNA with 11 kb molecular weight. DENV is a member of the family 
Flaviviridae (yellow fever virus is another type species of it), containing 
approximately 70 viruses [30]. Its genus is Flavivirus. The flaviviruses 
are comparatively small (40–50 mm), spherical at the same time having 
a lipid E. There are three major complexes within this family that include 
tick-borne encephalitis virus, Japanese encephalitis virus, and DENV. 
All flaviviruses have common group epitopes (antigenic determinants 
or these are the regions of proteins that can trigger a cellular immune 
response mediated by T or B cells) on the E protein which may result 
in wide cross-reactions in seroprevalence. These make an indisputable 
serologic diagnosis of flaviviruses difficult. This is specifically true among 
the four DENVs [31]. This RNA gets translated to a single polyprotein 
that encodes for three structural proteins, identified as capsid (C), pre-
membrane (prM), and envelope (E), and the 7 non-structural proteins 
(namely, NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). It is made of a 
single open reading frame and two non-coding regions (NCRs) present at 
the 5’and 3’ ends. It can be manifested as a single polyprotein precursor. 
It gets post-translationally cleaved by viral and host proteases. The 5’ 
and 3’ NCRs contain secondary structures and conserved sequences 
intricate the regulation of viral replication. Protein synthesis takes place 
in the cytoplasm on the rough endoplasmic reticulum (RER), and the 
structural proteins get anchored to the endoplasmic reticulum (ER) on 
the luminal side, where assembly and maturation of virion occurs.
A mature DENV shows that it is ∼50 nm in diameter and consists of an 
outer protein shell (E and M), a lipid bilayer, and a reduced outlined 
Nucleo C core (C and RNA genome). DENV shows different surface 
structures during its maturation and infection. These conformational 
remolds are apportioned to the inherent flexibility of the E protein. E 
protein is made up of three domains, namely, EDI (red), EDII (yellow), 
and EDIII (blue) and transitions between its oligomeric states are 
financed by the hinge motion, which occurs between EDI-EDII and EDI-
EDIII. On the other hand, a spiky appearance is seen in an immature 
virus particle (60 trimeric surface spikes, each consisting of three prM-E 
heterodimers). These immature particles are then transported through 
the cellular secretory pathway to the extracellular environment. The 
membrane-anchored protein M gets generated by cleavage of prM with 
furin and also the soluble product pr. In the mature phase (infectious 
virion), the pr peptide is not present and the virus undergoes membrane 
fusion in the endosome at low pH which leads to rearrangement of the 
E proteins into 90 homodimers of E that lie flat against the viral surface, 
giving a smooth appearance. In an E dimer, the E monomers are arranged 
vis a vis with their long directions antiparallel to each other. M remains 
docked to the lipid bilayer below the E protein shell. Infection with one 
of the four serotypes provides persisting immunity to that virus, but no 
cross-protective immunity can be obtained against the other serotypes. 
Therefore, persons living in an area of endemic dengue can be infected 
thrice, may be 4 times by dengue serotypes [32].
PATTERN OF TRANSMISSION
Aedes mosquitoes primarily transmit DENV, unusually A. aegypti. 
The latitudes of 35°N and 35°S below an elevation of 1000m (3300 
feet) are the place of survival of these mosquitoes [33]. During the 
day, particularly in the early morning and in the evening, they mostly 
bite [34]. A lifelong immunity may be produced if a person gets infected 
with any of the serotype; parallelly, the same person may get only short-
term protection against the other four serotypes (Table 1) [35]. The risk 
of severe disease increases from secondary infection if a person who was 
previously exposed to serotype DENV-1 contracts serotype DENV-2 or 
DENV-3, conversely if a person previously exposed to DENV-3 acquires 
DENV-2 [36]. People with chronic diseases such as diabetes mellitus 
and asthma may undergo life-threatening risks. Polymorphisms (occurs 
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when there are multiple alleles expressed within the population) also 
add to the cause of complications. Examples of affected genes coding 
for the proteins recognized as tumor necrosis factor α, mannan-binding 
lectin, cytotoxic T-lymphocyte-associated protein 4, transforming 
growth factor β [37], dendritic cell-specific intercellular adhesion 
molecule-3-grabbingnon-integrin (DC-SIGN), phospholipase C epsilon 1 
[38]. A common genetic abnormality that is glucose-6-phosphate 
dehydrogenase deficiency, among people from Africa in particular, pop 
up to increase the risk [32]. The Vitamin D receptor and Fc gamma 
receptor for polymorphisms in the genes materialize protection against 
severe disease in case of secondary dengue infection.
REPLICATION STAGE OF VIRUS
DENV once gets entry to the skin it binds to Langerhans cells (dendritic 
cells in the skin which works in surveillance for pathogens). The 
binding of viral proteins with membrane proteins on the cells makes 
the way easy for the entrance of the virus, most prominent the C-type 
lectins identified as DC-SIGN, mannose receptors, and C-type lectin 
domain family 5 member A. DC-SIGN is popularly a nonspecific receptor 
on dendritic cells basically for the foreign material; it seems to be the 
key point of entry. The dendritic cell then locomote to the approaching 
lymph node. Concurrently, inside the membrane-bound vesicles, 
the virus genome is translated. It is linked with the cell’s ER. It is the 
apparatus of cell’s protein synthesis where the new viral proteins are 
produced which in turn copy the viral RNA and begin to assemble 
viral particles. The portion of the cell is Golgi apparatus where the 
proteins accept necessary sugar chains (glycoproteins) where the 
immature virus particles get transported. The cleavage of the precursor 
membrane protein prM to its M form then occurs. Inside the cell, 
the mature new virus buds then released by exocytosis. They obtain 
the ability to invade other white blood cells, such as monocytes and 
macrophages. Production of interferon mainly by interferon-stimulated 
genes or ISGs (interferon is a cytokine that hoists a number of defenses 
against viral infection by the innate immune system by supplementing 
the production of a large group of proteins) is the initial reaction in 
response by the infected cells. Some serotypes of DENV reported to 
show mechanisms to slow down this process arbitrated by the Janus 
kinase signal transducer and activator of transcription pathway also 
called as the JAK-STAT pathway. The adaptive immune system cells get 
activated by ISGs, which in turn generates the antibodies specific for 
the virus and T cells at the same time that attack infected cells directly. 
Various antibodies are generated among which some bind tightly to the 
viral proteins and mark them specifically for phagocytosis (a process of 
ingestion by specialized cells and in turn destruction) whereas, others 
bind the virus not tight instead target to deliver the virus into a part 
of the phagocytes (their name comes from the Greek phagein, “to eat” 
or “devour,” and “cyte,” denoting “cell,” from the Greek kutos, “hollow 
vessel.” They are the cells that protect the body by ingesting harmful 
foreign particles, bacteria, and dead or dying cells). The viruses are not 
destroyed there but able to replicate further [37].
DEVELOPMENT OF INFECTION AFTER VIRUS ENTRY
The primary target of DENV infection in mosquitoes is the epithelium of 
the midgut, it first replicates there and then [39] spreads to and replicates 
further in salivary glands, from where the infection is transmitted 
through saliva to the corresponding vertebrate host during the blood 
feed. The virus enters the skin along with the mosquito’s saliva when a 
mosquito carrying DENV bites a person. It enters the white blood cells 
after binding to it and then reproduces inside the cells and eventually 
moves throughout the body. Infected cells carry the virus to lymph nodes; 
it, in turn, replicates there and results in viremia. A number of signaling 
proteins are produced by the WBC in response to the virus entry, which 
includes interferons and other cytokines. Nonspecific symptoms such as 
fever, headache, joint pain, and muscle pain develop as a response to it. 
Virus production inside the body is greatly escalated in severe infection, 
and various organs (such as liver and bone marrow) may be affected. 
Due to endothelial dysfunction, fluid from the bloodstream leaks through 
the wall of small blood vessels into body cavities. It results in less blood 
circulation and sometimes shock. Moreover, bone marrow dysfunction 
because of the stromal cells infection scan results in the development of 
thrombocytopenia, for which the bleeding risk gets uplifted along with 
other major complications [40].
CLINICAL REPRESENTATIONS AND OTHER ASSOCIATED 
PROBLEMS
Some associated problems include:
•	 Severe joint and muscle pain
•	 Rashes
•	 Severe pain behind eyes
Table 1: Cases of dengue as reported in West Bengal


















2018 Not reported Not reported
2019 Not reported Not reported
2020 (till 30th September) Not reported Not reported
Healthy person Infected person
Infected mosquito
Incubation period: 3–14 days
Most commonly: 4–7 days
Fig. 1: Pattern of transmission of dengue from one infected person to another
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An incubation period is believed to be of 3–7 days, after which all of a 
sudden, symptom prevails following three phases [41].
• An initial febrile phase
• A critical phase around the time of defervescence (the abatement off 
ever as indicated by a decrease in body temperature) and
• A spontaneous recovery phases.
Initial febrile phase
High temperature (≥38.5°C), along with headache, vomiting, myalgia, 
joint pain, and transient macular rash, is typical of this phase. Adults 
develop more specific symptoms of fever than that child in this phase. 
Lenient hemorrhagic manifestations such as petechiae (these are tiny 
purple, red, or brown spots on the skin) and bruising (the blood from 
damaged blood cells deep beneath the skin gather near the surface 
of the skin results in skin discoloration), particularly at venipuncture 
(it is a procedure where a needle is used to withdraw blood from a 
vein for laboratory testing) sites (the antecubital area of the arm is 
commonly the first choice for routine venipuncture). This area contains 
the three vessels primarily used by the phlebotomist to obtain venous 
blood specimens those are the median cubital, the cephalic, and the 
basilic veins) and a palpable liver is usually noted. Mild-to-moderate 
thrombocytopenia and leukopenia, sometimes with a moderate 
increase of hepatic aminotransferase levels, are common by laboratory 
uncovering. This initial phase lasts for 3–7 days on average, after which 
most patients redeem unaccompanied by any complications.
Critical phase accompanied with reduced body temperature
A systemic vascular leak syndrome becomes evident during this phase 
in a negligible proportion of patients, specifically in children and young 
adults which is noticed by upliftment of hemoconcentration (a decrease 
in plasma volume), hypoproteinemia (low level of protein than normal), 
pleural effusions (accumulation of fluid within the tissue that lining the 
chest and lung), and ascites (accumulation of fluid in peritoneal cavity 
which cause swelling of the abdomen). At first, to maintain proper 
circulation to vital organs, physiological compensatory mechanisms 
(an action performed by the body to continue physiological function in 
spite of a change in natural function) are up-regulated. This leads to 
diminishing the pulse pressure with serious loss of plasma volume. If 
the reduction in pulse pressure occurs nearly to 20 mm Hg or less than 
that, the signs of peripheral vascular collapse accompany, diagnosis of 
dengue shock syndrome prevails with urgency, but careful reinvigorate 
needed. Elevated systolic pressure may be noticed at this time in the 
well deceptive patient. With the development of hypotension, systolic 
pressure reduces rapidly following irreversible shock and death in spite 
of hostile attempts at resuscitation. When the shifting to the critical 
phase from the febrile phase occurs between 4 and 7 days of illness, it 
becomes critical for the clinician to be aware of alarming signs that turn 
into effect. Clinically significant vascular leakage may be seen among 
the patient. Persistent vomiting, increasingly severe abdominal pain, 
tender hepatomegaly (enlarged liver), a high or increasing hematocrit 
level, common signs appear during this time with a simultaneous and 
rapid decrease in the platelet count, serosal effusions, mucosal bleeding, 
and restlessness, the most significant symptom being hemorrhagic 
manifestations. Rarely bleeding occurs, usually in association with 
profound and prolonged shock, which becomes clinically significant in 
the case of children. However, in the case of adults-only minor plasma 
leakage and major skin bleeding, mucosal bleeding (gastrointestinal or 
vaginal), or both may appear with no obvious precipitating factors [42]. 
Moderate to severe thrombocytopenia is common, with nadir platelet 
counts below 20×109/L often observed during the critical phase, 
followed by rapid improvement during the recovery phase. A transient 
increase in the activated partial-thromboplastin time and a decrease in 
fibrinogen levels are also frequently noted. However, the coagulation 
profile is not typical of disseminated intravascular coagulation, and the 
underlying mechanisms remain unclear [43]. Infrequently, other severe 
manifestations, including liver failure, Myocarditis, and encephalopathy, 
occur, often with minimal associated plasma leakage.
Recovery phase
After more or less 48–72 h, the altered vascular permeability reverts 
to a normal level with rapid refinement in the symptoms associated 
with the patients. During the recovery phase, a second rash may appear, 
extending from a mild maculopapular rash to a severe type, itchy 
lesion suggesting leukocytoclastic vasculitis (vasculitis is a group of 
disorders that destroy blood vessels by inflammation) that settles with 
desquamation over and above a period of 1–2 weeks. Profound fatigue 
for several weeks after recovery in adults may be seen.
OTHER ASSOCIATED PROBLEMS
Infrequently dengue affects other body organs [44], be it in isolation or 
with the superior symptoms that occurs during dengue [45]. Nearly in 
0.5–6% of severe cases, there is the occurrence of reduced consciousness 
level which is traceable to encephalitis or indirectly to damage of key 
organs (e.g., hepatic encephalopathy) [46]. Other neurologic disorders 
such as transverse myelitis and Guillain-Barre syndrome have found to 
appear in the background scene of dengue. The rarest complications 
involve Myocarditis and acute liver failure [47].
LABORATORY DIAGNOSIS FOR THE INFECTION
A conclusive diagnosis of dengue infection can be availed only in the 
laboratory and that depends on
• The virus isolation
• Viral antigen or RNA in serum or tissues detection or
• Specific antibodies in the patient’s serum detection [48].
Virus isolation
Typically, four isolation systems have been found to be used for dengue 
virus detection, namely:
• Intracerebral inoculation of 1–3-day-old baby mice
• The use of mammalian cell cultures (primarily LLC-MK2 cells)
• Intrathoracic inoculation of adult mosquitoes and
• The use of mosquito cell cultures [49].
Baby mice
Initial isolation of all four dengue serotypes from human serum using 
baby mice was done [50], but still, this method is very time-consuming 
and lavish at the same time. Moreover, various wild type virus is unable 
to be isolated from the baby mice because the method gives a delicate 
response. Still, those that are isolated time and again demand numerous 
passages for virus adaptability and growth in mice. Some laboratories 
continue this method though it is ill-advised [51]. In addition, one 
advantage of using baby mice is that other arboviruses may be isolated 
that cause dengue-like illness.
Mammalian cell culture
Mammalian cell culture method is similar to the above method and 
has similar disadvantages for isolation of DENVs, such as being 
expensive, time-consuming, and insensitive [52]. Similarly, as with 
seclusion frameworks that utilization of infant mice, infections that 
are disconnected as often as possible require numerous entries before 
a predictable cytopathic impact can be seen in the tainted societies. 
Despite the fact that the utilization of this technique proceeds in a few 
research facilities, it is not suggested.
Mosquito inoculation
The most effective method for DENV isolation is said to be the mosquito 
inoculation method [53]. Nearly 100% of serologically confirmed 
dengue infections can be isolated. This method is sensitive enough 
for schedule successful virologic confirmation of fatal DHF and DSS 
cases [54]. Most importantly, many endemic DENV strains can be 
recovered with this method only [55]. Four mosquito species, namely, 
A. aegypti, A. albopictus, Toxorhynchites amboinensis, and Tetramorium 
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splendens are being used for isolation of virus. Both male and female 
mosquitoes are fairly sensitive. DENVs generally replicate to high 
titers (A laboratory test that measures the presence and number 
of antibodies in blood) in <4–5 days, depending on incubation 
temperature. Replication of DENVs can occur in most mosquito tissues 
together with the brain. In this method, a recent variation necessitates 
intracerebral inoculation of larval and adult Toxorhynchites mosquitoes 
[56]. But the mentioned alteration doesn’t impart  Any expanded 
sensitivity nor any other advantages over intrathoracic inoculation 
[57]. In general, the direct fluorescent-antibody DFA test on mosquito 
tissues is the basis of virus detection in mosquitoes belonging to any 
species using specifically brain or salivary glands [58]. The direct 
conjugate prepared from pooled human serum (it is an ideal negative 
diluent for assay development and manufacture) shows a vast reactive 
anti-dengue (or anti-flavivirus) activity. As a replacement, a polyclonal 
mouse ascitic fluid or a flavivirus group-reactive monoclonal antibody 
can be handed down in an indirect fluorescent-antibody (IFA) test with 
an anti-mouse immunoglobulin G-fluorescein isothiocyanate conjugate 
which is commercially convenient. The disadvantages of this technique 
is it is labour meticulous and there is a need of an insectary to produce 
large numbers of mosquitoes for inoculation. In addition, chances of 
laboratory infection come to rule if not strict safety precautions are 
maintained. If male Aedes mosquitoes or nonbiting Toxorhynchites 
species are regular for inoculation, then the chances of risk can be put 
to an end [59].
Mosquito cell culture
The most recent inclusion to DENV isolation methodology is the 
mosquito cell culture [60], where comparable sensitivity of three cell 
lines used over and after [61]. The first cell line still the most widely 
used has been developed and is the C6/36 clone of A. albopictus 
cells [62]. A rapid, sensitive, and economical method for DENV 
isolation can be achieved using these cell lines. Consequently, a large 
number of serum specimens can be fixed easily, making the method 
very suitable for routine virologic surveillance [63]. Still, this system 
is less inactive than mosquito inoculation [64]; as an example, viruses 
isolated from patients in Puerto Rico were nearly 10 to 15% by 
the mosquito inoculation technique than by mosquito cell cultures 
method [65]. Although, the strain of the virus is a point of variation in 
the sensitivity of the mosquito cell lines method. By DFA or IFA tests, 
dengue antigen can be detected in infected-cell cultures using the 
conjugates used for mosquito tissues [66]. The mosquito cell culture 
method alone will fail to detect many DENVs which do not replicate so 
fast in mosquito cells [67]; still, this is the method of choice for typical 
virologic surveillance where a large number of samples can be detected 
and processed in a short interval of time depending upon the facilities 
available in the laboratories.
Virus identification
The method of choice for DENV identification is IFA with serotype-
specific monoclonal antibodies that are produced in tissue culture or 
mouse ascitic fluids and an anti-mouse immunoglobulin G-fluorescein 
isothiocyanate conjugate [68]. It is said to be simple, reliable, and is 
the fastest method of identification. Infected cell cultures, mouse brain 
squashes, formalin-fixed tissues embedded in paraffin, and sectioned 
for histopathologic testing mosquito, brain, or tissue squashes, can 
be used for this technique. Patients with coexisting infections with 
diverse serotype can also be easily detected by this method [69]. With 
the appearance of IgM antibody, the attainment of virus isolation goes 
down briskly [70]. Apparently, viremia (a condition when virus enters 
into the bloodstream meaning of the word comes from combining 
“virus” with the Greek word for “blood” [Haima]) may remain below 
the base of detection throughout the illness as noted with some virus 
strains [71]. Various factors involved in the attainment of isolation of 
DENV from human serum [72].
• The storage and handling of the specimen is the most important 
factor. Heat, pH, and several other chemicals can diminish the virus 
activity.
• The time after onset, the strains of infecting virus greatly affect the 
level of viremia. Usually, viremia culminates or shortly before the 
onset of illness, which may be detectable within an acceptable time 
limit of 4–5 days [73].
Detection from patient’s serum
The existing scenario of the different methods of diagnosis after 
manifesting their practicality is up growing. Some of those are 
mentioned below:
Reverse transcription-polymerase chain reaction (RT-PCR)
RT-PCR is sensitive enough to enable detection and quantitation of RNA 
from even a single cell. RT-PCR uses RNA as starting material for in vitro 
nucleic acid amplification. In the present time, this method showed the 
potential to restructure laboratory diagnosis for dengue. A swift serotype 
(a marked variation within a species of bacteria or virus or among 
immune cells of different individuals) specific diagnosis can be obtained 
by RT-PCR. It can be called as a rapid, non-complex, sensitive, and 
reproducible method of viral RNA detection in human clinical samples, 
autopsy tissues, or mosquitoes if controlled in a proper way [74]. Even 
though RT-PCR is with akin or similar sensitivity when compared to 
virus isolation systems that use C6/36 cell cultures but the outcome of 
PCR is not influenced by imperfect handling, storage, and the presence of 
antibody. Primers from different locations in the genome involve various 
methods and approaches to detect the RT-PCR products which have 
been evolved over the past years. It must be spotlighted that RT-PCR 
should not be used as a substitute for virus isolation as the virus isolates 
is inevitable for specifying virus strain differences for viral surveillance 
and pathogenesis studies. Many laboratories are now performing RT-
PCR tests in the absence of proper quality control procedures, that is, 
virus isolation or serologic testing. As sensitization to amplicon (it is a 
piece of DNA or RNA which is the source and/or product of amplification 
or replication events. Artificially it can be created with different methods 
that involve PCRs or ligase chain reactions, or naturally, through gene 
duplication); contamination is an issue related to RT-PCR, if not 
controlled properly, then false-positive results may obtain.
Hybridization probes
Viral nucleic acids with cloned hybridization probes can be detected by 
this method. Irregular specificity with a probe extending from dengue 
complex to serotype-specific depending on the genome sequences used 
can be assembled. This relatively rapid and simple method can be used 
on human clinical samples as well as fixed autopsy tissues. However, 
hybridization probes have not been so vast in use or evaluation in 
the diagnostic laboratory. This method is not so sensitive as RT-PCR 
as suggested by initial data, the presence of neutralizing antibodies 
or other inhibitory substances do not influence the test results like 
PCR. Moreover, the problems of working with RNA and the technical 
expertise indispensable to obtain reproducible results build this 
method much more promising as a research tool as compared to a 
routine diagnostic test [75].
Immunohistochemistry
The proper diagnosis and confirmation of the fatal cases in the 
laboratory are a most important challenge. In many cases, the serologic 
testing comes to a standstill because of the existence of a single 
serum sample. Most of the patients are unable to survive at the time 
of or somewhat after defervescence when isolation of virus becomes 
difficult. With new approaches of immune histochemistry, dengue viral 
antigen can be identified in a diverse type of tissue [76]. In the past day, 
immunofluorescence tests were used. Novel approaches which include 
enzyme conjugates such as peroxidase and phosphatase in conjunction 
with either polyclonal or monoclonal antibodies are specifically 
identified and showed promising responses.
CONTROL AND PREVENTIVE MEASURES
The preliminary way to dominate A. aegypti, main vector transmitting 
virus of dengue, is by eradicating its habitats. It mainly survives in 
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water logging urban areas (e.g., ponds, clogged drains, discarded tires, 
drainage ditches, and open barrels) [77].
Chemical control
To control the spread of dengue, chemicals should be distinctively added 
to water that is usually stored for domestic use which at the same time 
includes the drinking water. The International Programme on Chemical 
Safety assessed the effective and functional ingredients of four larvicides 
and concluded that they are safe for use in drinking water at dosages and 
they also added their worth against Aedes spp. larvae [78]. The vector 
control plan from the last few years was going through the ultimate 
use of various insecticides derived from plants and chemical origin. 
There are certain sides effects which have negative impacts on the 
environment associated with the deep-rooted use of insecticides [79]. 
However, various alternative ways come in the run with the scientists 
to overcome these problems, such as derivatives of plants or herbal 
derivatives certain potential repellents made of those derivatives 
having comparatively less side effects [80]. These alternative agents 
were proved to be less toxic to both environments and mosquitoes with 
sustained effects. In addition to these, some insect growth regulators 
(IGRs) like chemical compounds are used for regulating the growth 
and development of the insect at its initial stage and eventually killing 
the insect resulting the inhibition of adult stage development. Among 
various IGRs, pyriproxyfen, methoprene spinosad diflubenzuron, and 
cyromazine are some reported chemical compounds for larval control 
and progressively reduce the populations of A. aegypti [81].
Biological control
The removal of mosquito also includes the addition of biological agents 
to standing water. Biological agents such as larvivorous fish (a south 
American native species is Poecilia reticulata [Guppy] and native of 
Texas is Gambusia affinis [Gambusia] were imported in India in 1908 
and 1928 purposely for vector control) and copepods (they are a group 
of small, freshwater and saltwater crustaceans of subclass Copepoda), 
found to play a demonstrable role in dominating A. aegypti [82]. 
Sometimes it is not that much effective to spray organophosphate 
or pyrethroid insecticides [83]. Reducing open collections of water 
through environmental modification is the preferred method of control, 
given the concerns about negative health effects from insecticides and 
the greater logistic difficulties associated with control agents. The 
basic control of dengue vector can be planned using biological agents, 
but the conventional methods were found to be unprofitable again 
the mosquitoes which bite in the daytime, so the novel approach may 
include the genetically modified mosquitos [84], another traditional 
control measure popular as sterile insect technique became successfully 
for several years in different countries. It works by harming the health 
of male insects, in turn reducing the ability to compete for wild-type 
female insects for breeding [85]. Other approach involves the loose 
turn of transinfected mosquitoes that can transmit the intracellular 
bacterium Wolbachia [86]. Commonly Wolbachia is safe; it is present 
in almost 60% of insect species naturally, including butterflies, moths, 
and some other kinds of mosquitoes. Wolbachia help in controlling 
the mosquito population in two different strategies which include the 
turning down of reproductive capacity of the vector and suppressing 
the replication of RNA. Nevertheless, Wolbachia is not effective against 
the primary species of mosquito A. aegypti which is taken as the cause 
of dengue and other flaviviruses transmission [87]. As Wolbachia 
and virus both need iron and cholesterol for replication and growth, 
Wolbachia act by competing and consuming iron and cholesterol and 
thereby creating a situation tough for the virus to grow further and 
replicate [88]. Another approach by the scientist is to build a strong 
immune system of the mosquito to resist the infection caused by the 
virus, which in turn will instigate various signaling pathways, including 
JAK-STAT, Toll, and immune deficiency. This pathway will provide the 
strongest resistance against various arboviruses [89]. Besides using 
Wolbachia as a tool for controlling the vector spread, it is important at 
the same time to assess the invasion of mosquitoes into the environment 
that is Wolbachia-infected because they can cause a shift to wild-type 
populations in field conditions [90].
Other ways to prevent mosquito bites are by wearing clothing fully 
covering the skin, repellent on cloths can be used, staying in air-
conditioned, netted, and screened areas [91]. However, these methods 
do not appear to be much promising, as the outbreak is uplifting 
drastically in some areas due to the urbanization of Aedes mosquito 
habitat as well as changes in the climate as the captivating cause [92].
VACCINATION
The failure of vector control and the persisting increase and spread 
of dengue has resumed interest as well as investment in dengue 
vaccine development. Taking public health globally as a priority an 
effective, safe, and affordable tetravalent dengue vaccine finds its way 
toward development [93]. Attempts for this development of vaccines 
started nearly 90 years ago 12, 13 still the attainment of success so 
far was limited [94] because the illness was identified with complex 
pathological mechanism and controlling all four serotypes with the 
immunogenic response at the same time and lower rate investment by 
vaccine developers have restricted the advancement [95].
Dengvaxia
CYD-TDV is sold under the brand name of Dengvaxia that is made 
by Sanofi Pasteur. It is a live attenuated chimeric vaccine which is 
tetravalent in nature. It was made using recombinant DNA technology 
by replacing PrM and E structural genes of yellow fever attenuated 17D 
strain vaccine with those from the four each DENV serotype and are the 
most advanced type. This vaccine, after going through various trials, got 
permission to be introduced further on May 1, 2019. The efficacy and 
safety protocols were tested in placebo-controlled clinical trials with 
almost 35,000 children of 2–16 years old. These tests were performed in 
10 countries which were specified as dengue-endemic places [96]. The 
effective results obtained were mixed. After 3 years and after the initial 
dose, almost 65.5% children of 9 years old got the vaccine protection 
against hospitalization. However, nearly 44.6% protection was noticed 
among the children with age of 8 years and less. In the age group 
between 2 and 5 years, rate of hospitalization was as frequent as 5 times 
even after vaccination as compared with the placebo group. Amidst 
the 11% of children with confirmed serostatus (when vaccinated), 
the protection in seronegative children of age 8 years old or younger 
than that was 14.4% but in those of age 9 years or older was found 
to be 52.5%. These data guided the expert to recommend that vaccine 
for the age group of 9 years or older than that but restricted for the 
children <9 years old [97]. With the novel serological test, it is possible 
to differentiate the seronegative population from those who were 
dengue-immune at the time of vaccination [98]. With the application 
of this test to sera from a 10% randomized cohort of phase 3 children, 
seronegativity of dengue relative to the age-controlled menace to severe 
hospitalized dengue illness where the platelet count of <100,000 mm3 
and vascular permeability was evidenced over the period 5–6 years 
after the initial dose in children given vaccine [99]. The World Health 
Organization (WHO) Scientific Advisory Group of Experts, the Global 
Advisory Committee on Vaccine Safety, and the WHO Dengue Vaccine 
Working Group in 2016 recommended with the evidence and incidence 
of shrinking efficacy of that vaccine that it could be given to individuals 
with investigated dengue infection or to populations with 80% DENV 
seroprevalence [100]. Dengvaxia fails to protect seronegative children 
because it was found that when vaccinated, the children developed 
dengue illness when the circulating tetravalent DENV neutralizing 
antibodies was persistent which provided a solid affirmation that 
conventionally measured human neutralizing antibodies were not 
protective [101]. Present observations indicate that it may be important 
to redefine the design of classic neutralization tests. When recovery 
of live DENV1 virus from humans during the acute phase of dengue 
infection was used to measure neutralization by antibodies, only the 
neutralization obtained by homotypic antibodies. Similar envelop or E 
proteins are found in DENV, as a result during infection, cross-reactive 
(heterotypic) antibodies against all DENV types are formed. As DENV 
types are immunologically distinct so they induce the production of 
antibodies that are type-specific (homotypic). Another explanation for 
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Dengvaxia, fail to protect is that antibodies which were augmented by 
vaccine may be not highly matched to the specific DENV genotypes in 
circulation. The variations at three positions on the E protein of DENV4 
strongly correspond with vaccine efficacy as demonstrated by Juraska 
et al. [102]. The three amino acid positions set up to a region on E 
protein that can be recognized by strongly neutralizing antibodies in 
people already infected with DENV4 [103].
TAK 003
The Takeda Pharmaceutical Company (Tokyo, Japan) in January 2018 
reported the completion of phase 3 trials for TAK 003 [104], but its 
efficacy and safety protocols were not published. The main embody of 
this vaccine is a live-attenuated DENV2 strain and three chimeric viruses 
consisting of the prM and E protein genes of DENV1, 3, and 4 that are 
expressed on the backbone of the DENV2 genome [105]. Among these 
viruses, DENV2 16881 PDK 53 is a promising vaccine candidate and 
this virus executed an exceptionally high level of seroconversions in 
seronegative human volunteers with the least dengue signs or symptoms 
[106]. This vaccine also consists of structural DENV1, 3, and 4 proteins 
that are expressed on a DENV2 backbone. The investigators hope for 
expanding protection against all DENV infection/disease based on the 
vast neutralizing antibody responses which follow two doses of TAK 003.
Live attenuated tetravalent dengue vaccine (LATV)
The National Institute of Allergy and Infectious Diseases and the Johns 
Hopkins Bloomberg School of Public Health for almost 20 years have 
tried, designed and tested dengue vaccine candidates. Among all, the 
nucleotide removal from non-translated regions of dengue genome gave 
rise to attenuated one. The testing of vaccine candidates of monovalency 
for immunogenicity and attenuation in seronegative human volunteers 
is a crucial part of this development program [107]. A final product or 
the LATV includes mutated DENV 1, 3, and 4 and a chimera of structural 
DENV 2 over a DENV 4 backbone [108]. With a single dose of LATV, the 
volunteers get protected from viremia, different dengue symptoms, 
or anamnestic antibody responses succeeding challenge with non-
parental strains that were wild of live DENV2. This protection gave a 
sustained effect which is evidenced by the absolute immune response 
observed to a booster dose of live-attenuated vaccine that was given 12 
months following the initial dose [109]. The results of protection are 
complemented by evidence that a unique or single dose of LATV uplift 
amino specific neutralizing antibody which is conformationally akin to 
antibodies increased after human infections with wild-type DENVs that 
corresponds with protection [110]. In addition, the T-cell responses to 
LATV sharply resemble to those raised after infections with wild-type 
DENVs. In the long run, LATV consists of the genes for three of the four 
DENV NS1 proteins and it is in the 3rd year of phase 3 clinical trial in 
Brazil. The prospect of LATV, depending upon phase 2 clinical trials 
in humans, is that a unit dose of this vaccine will improve durability 
and provides solid protection against dengue infections in not only 
seronegative but also in seropositive.
CONCLUSION
Finally, accentuation has been set on community-based ways to deal 
with larval source decrease to give program maintainability. The 
reasoning is that maintainable A. aegypti control can be refined simply 
by the individuals who live in the houses where the issues happen 
and by individuals who help make the mosquito larval environments 
by their ways of life. Network investment in and responsibility for 
programs requires broad wellbeing training and network outreach. 
Tragically, this methodology is an extremely moderate cycle. Thusly, 
it has been suggested that a mix top-down furthermore, base-up 
methodology be utilized, the previous to make quick progress, and the 
last to give program maintainability. The adequacy of this methodology 
stays obscure. Mosquito control for dengue counteraction has as of late 
been assessed. With the increased global incidences of dengue and no 
specific treatment available for the same, early detection of the disease 
and its progression to severe dengue is of utmost importance so that 
proper medical care can be accessed so as to lower the fatality rates. 
Effective vector control measures can help dengue prevention and 
sustained community involvement can improve the vector control 
efforts. Other perspective for mosquito control is also available these 
days and it can be said that in the future, the lesser percent of disease 
that is prevailing can be overcome by the several methods of mosquito 
control, development of vaccine, and antiviral drug regimen. There 
is no totally compelling technique for forestalling dengue disease in 
explorers visiting tropical territories. The danger of disease can be 
altogether diminished, in any case, by understanding the essential 
conduct and taking care of propensities for the mosquito vector and by 
taking a couple of straightforward insurances to diminish presentation 
to infective mosquito nibbles. Female A. aegypti mosquitoes want to 
take care of inside, with top gnawing movement happening for 2–3 h 
after sunrise and for 3–4 h prior dusk. In spite of the fact that the 
danger might be higher at these occasions, it is essential to recollect 
that the mosquito may take care of inside at whenever during the day, 
just as outside, particularly on cloudy days. Precautionary measures, 
hence, incorporate remaining in screened or then again cooled rooms, 
showering these rooms with vaporized bomb bug sprays to murder 
grown-up mosquitoes inside (particularly in rooms), utilizing an 
anti-agent containing diethyl-meta toluamide on uncovered skin, and 
wearing defensive dressing treated with a comparative repellent. The 
danger of presentation may be lower in current, cooled inns with very 
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